GH Research PLC (NASDAQ:GHRS) Receives $34.11 Average Price Target from Analysts

GH Research PLC (NASDAQ:GHRS) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $34.1111.

Several brokerages have weighed in on GHRS. HC Wainwright lowered their target price on shares of GH Research from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Citigroup restated a “market outperform” rating on shares of GH Research in a report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Thursday, January 22nd. Guggenheim restated a “buy” rating and set a $29.00 price target on shares of GH Research in a research note on Monday, January 5th. Finally, Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in GH Research during the fourth quarter worth about $38,000. Osaic Holdings Inc. grew its holdings in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in GH Research during the 2nd quarter worth approximately $79,000. Virtus Investment Advisers LLC acquired a new stake in GH Research during the 2nd quarter worth approximately $89,000. Finally, BNP Paribas Financial Markets boosted its position in GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after buying an additional 10,600 shares during the period. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Stock Performance

Shares of GH Research stock opened at $16.06 on Monday. The stock has a 50 day moving average of $14.57 and a 200 day moving average of $14.03. The firm has a market capitalization of $835.60 million, a price-to-earnings ratio of -21.70 and a beta of 0.98. GH Research has a fifty-two week low of $7.98 and a fifty-two week high of $20.50.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). Analysts forecast that GH Research will post -0.8 EPS for the current year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.